Brian Fahie, Ph.D. currently is the Global Head of the Quality Control team at Biogen supporting the testing, characterization, and release of the Biogen commercial and late phase clinical portfolio (Proteins, Small Molecules, Antisense Oligonucleotides, and Devices). Prior to this role, Brian was responsible for the Analytical Development team at Biogen supporting the entire Product Development portfolio where he was responsible for the development of innovative testing strategies optimized around decision making and the strategic use of automated solutions and external partner capabilities and capacities.